NCT01933347View on ClinicalTrials.gov

Third-line Treatment of Gefitinib in NSCLC Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 7, 2014

Primary Completion Date

April 10, 2017

Study Completion Date

April 10, 2018

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Gefitinib

Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.

Trial Locations (1)

210002

Nanjing General Hospital of Nanjing Military Command, Nanjing

All Listed Sponsors
lead

Guangdong Association of Clinical Trials

OTHER

NCT01933347 - Third-line Treatment of Gefitinib in NSCLC Patients | Biotech Hunter | Biotech Hunter